RESULTS FROM THE FIRST 2 YEARS OF A CLINICAL TRIAL WITH RECOMBINANT DNA-DERIVED HUMAN GROWTH HORMONE (SOMATREM) IN TURNER'S SYNDROME
Bewaard in:
ROSENFELD, R.G., RESULTS FROM THE FIRST 2 YEARS OF A CLINICAL TRIAL WITH RECOMBINANT DNA-DERIVED HUMAN GROWTH HORMONE (SOMATREM) IN TURNER'S SYNDROME. ACTA PAEDIATRICA SCANDINAVICA, no. SUPL. 331 (1987), p. 59-66.
Ref.
1359
Plaats:
SIIS R.386 Depósito (26/29/30)
Palabras clave:
Genética, Síndrome de Turner, Tratamiento
Genética, Síndrome de Turner, Tratamiento
Gelijkaardige items: RESULTS FROM THE FIRST 2 YEARS OF A CLINICAL TRIAL WITH RECOMBINANT DNA-DERIVED HUMAN GROWTH HORMONE (SOMATREM) IN TURNER'S SYNDROME
- A MULTICENTRE TRIAL OF RECOMBINANT GROWTH HORMONE AND LOW DOSE OESTROGEN IN TURNER SYNDROME: NEAR FINAL HEIGHT ANALYSIS
- METHIONYL HUMAN GROWTH HORMONE IN TURNER'S SYNDROME
- GROWTH HORMONE TREATMENT IN GIRLS WITH TURNER'S SYNDROME
- GROWTH HORMONE TREATMENT IN TURNER'S SYNDROME
- METABOLIC STUDIES OF GROWTH HORMONE AND OESTRADIOLTREATMENT IN TURNER'S SYNDROME
- GROWTH HORMONE SECRETION IN TURNER'S SYNDROME AND INFLUENCE OF OXANDROLONE AND ETHINYL OESTRADIOL